However, our findings from GK and EPI cells show that this down-regulation of CDH1 caused by KRT5 inhibition is not a phenomenon of the final tumor-related cell transformation, i.e., the malignant tumor in vivo, but rather occurs at the beginning of the transformation process, i.e., if the cells are not yet tumorigenic. This evidence concerns the gene KRT5 and cancer.